Neuronetics Inc
(FRA:NRC)
€
1.875
-0.10 (-5.06%)
Market Cap: 143.72 Mil
Enterprise Value: 209.42 Mil
PE Ratio: 0
PB Ratio: 12.46
GF Score: 61/100 Neuronetics Inc at JMP Securities Life Sciences Conference Transcript
May 16, 2023 / 04:30PM GMT
Release Date Price:
€1.8
Daniel Stauder
JMP Securities LLC - Analyst
Welcome to day two of the JMP Life Sciences Conference. I'm pleased to introduce members of Neuronetics management team. We have CEO, Keith Sullivan; CFO, Steve Furlong. Before we get into it, just as a reminder, Neuronetics is a leader in the TMS space, treating a range of neurological disorders, primarily major depressive disorder.
Questions & Answers
Daniel Stauder
JMP Securities LLC - Analyst
So just with that, let's get going. Keith, you've been at the helm for almost three years now. We would love to hear your high-level perspective on where the TMS market stands right now, what has changed in the industry since you've joined, and where Neuronetics stands within that today.
Keith Sullivan
Neuronetics, Inc. - President & CEO
Very good. Well, thanks for having us.
Daniel Stauder;Keith Sullivan
JMP Securities LLC - Analyst;Neuronetics, Inc. -
Of course. Thank you for coming.
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
7-Day Free Trial · Cancel Anytime
Subscription fee may be tax deductible.
Excellent 

4.6 out of 5
Trustpilot